1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
VivoSim Labs, Inc.

VivoSim Labs, Inc.

VIVS
VivoSim Labs, Inc.US flagNASDAQ
0.28
USD
+0.00
- -
714,592.00Market Cap
VivoSim Labs, Inc.
VIVS
(NASDAQ)

Recent

price

0.28

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
- -
6.66
1.24
1.72
3.85
10.38
10.3
6.43
4.07
- -
2.07
0.51
0.14
0.1
0.05
0.05
Revenue per Share
-0.49
-242.24
-84.82
-90.64
-100.2
-94.38
-77.89
-55.4
-34.66
-29.25
-15.78
-23.77
-19.25
-1.7
-5.35
-5.38
Basic EPS, GAAP
-0.46
-55.9
-51.97
-63.63
-81.87
-74.97
-65.24
-42.55
-27.57
-23.87
-12.22
-17.63
-19.28
-6.47
-4.18
-4.21
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
-21.74
148.35
143.33
161.52
143.15
96.37
70.25
48.95
54.25
41.62
21.1
4.29
5.53
-0.38
-0.38
Book Value per Share
-0.02
-21.74
148.35
143.33
161.52
143.15
96.37
70.25
48.95
54.25
41.62
21.1
4.29
5.53
-0.38
-0.38
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
3
3
Basic Weighted Avg Shares
- -
1
- -
1
1
4
5
3
2
- -
2
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-778.53
-5,448.28
-5,305.95
-2,605.73
-911.94
-766.26
-882.37
-977.91
- -
-765.27
-4,792.16
-13,840.37
-8,761.11
-8,768.7
-8,768.7
Operating Margin (%)
- -
- -
- -
- -
1
1
1
1
1
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-44
-26
-30
-39
-38
-35
-27
-19
-17
-11
-17
-15
-2
-14
-14
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-3,638.51
-6,820.05
-5,268.3
-2,601.15
-908.91
-756.09
-861.7
-852
- -
-763.2
-4,664.59
-13,459.63
-1,727.78
-10,567.18
-10,567.18
Profit Margin (%)
- -
-6
47
47
59
59
42
35
27
38
28
13
2
8
4
4
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
1
1
- -
- -
- -
LT Debt
- -
-5
48
49
62
62
45
36
27
39
30
15
4
10
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-62.04
-69.58
-61.74
-65.08
-65.86
-59.46
-51.12
-32.99
-75.8
-155
-35.31
- -
-112.51
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1
1
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3
3
3
Market Capitalization
8
5
4

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
8
6
7
Cash, Cash Equivalents & STI
7
4
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
3
Payables & Accruals
1
1
2
ST Debt
1
1
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-9.41%
-13.56%
-110.47%
Free Cash Flow
-6.99%
0.51%
14.28%
Net Income, GAAP
30.4%
75.43%
456.39%
Sales/Revenue/Turnover
- -
-30.9%
-9.03%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-5.54
-5.5
-4.74
- -
-19.25
2025
-2.74
-1.7
-2.29
- -
-1.7
2026
-1.14
-0.98
-1.03
- -
-5.35

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
Basilea Pharmaceutica AG (0QNA.L)
Tempest Therapeutics, Inc. (TPST)
Oryzon Genomics S.A. (0RDB.L)
Orthocell Limited (OCC.AX)
NextCell Pharma AB (NXTCL.ST)
Business
I did not find relevant results on recent major changes specifically for VivoSim Labs, Inc. (Ticker: VIVS) in the initial search. I will conduct a more targeted search using the company name and ticker specifically with focus on products, latest offerings, partnerships, and corporate news.

Company News

Company News APIChatGPT

  • globenewswire.com

    VivoSim Labs to Add Rat Liver Model to NAMkind Platform

  • globenewswire.com

    VivoSim Provides Financial and Listing Compliance Update

  • globenewswire.com

    VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services

  • globenewswire.com

    VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor

  • globenewswire.com

    VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027

  • globenewswire.com

    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

  • globenewswire.com

    VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting

  • globenewswire.com

    VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing

  • defenseworld.net

    Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%

  • globenewswire.com

    VivoSim Announces Pricing of up to a $4 Million Public Offering

  • defenseworld.net

    Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)

  • globenewswire.com

    VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs

  • defenseworld.net

    VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update

  • globenewswire.com

    VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales

  • defenseworld.net

    VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

  • globenewswire.com

    VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego

  • globenewswire.com

    VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China

  • defenseworld.net

    Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)

  • defenseworld.net

    VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis

  • globenewswire.com

    VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer